4 results on '"Lozupone VA"'
Number of results to display per page
Search Results
2. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy
- Author
-
Sandro Feriozzi, Leonardo Cagnoli, Annalisa Foschi, Vincenzo Panichi, Francesco Bianco, Deni Aldo Procaccini, Antonio Pisani, Fabrizio Martinelli, Giacomo Torti, Antonio Cioni, Vito Antonio Lozupone, Maria Laura Cossu, Antonio Giudicissi, Francesco Marchini, Letizia Spinelli, Fausto Soliani, Cristina Comotti, Elena Ragazzoni, Bruno Cianciaruso, Eliana Gotti, Renzo Mignani, Andrea Serra, Massimiliano Veroux, Mignani, R, Feriozzi, S, Pisani, Antonio, Cioni, A, Comotti, C, Cossu, M, Foschi, A, Giudicissi, A, Gotti, E, Lozupone, Va, Marchini, F, Martinelli, F, Bianco, F, Panichi, V, Procaccini, Da, Ragazzoni, E, Serra, A, Soliani, F, Spinelli, Letizia, Torti, G, Veroux, M, Cianciaruso, Bruno, and Cagnoli, L.
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,urologic and male genital diseases ,End stage renal disease ,Agalsidase ,Ventricular Dysfunction, Left ,renal replacement ,Internal medicine ,medicine ,Humans ,Renal replacement therapy ,Prospective Studies ,Registries ,Dialysis ,Kidney transplantation ,Aged ,Transplantation ,Fabry disease ,business.industry ,Enzyme replacement therapy ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Recombinant Proteins ,Surgery ,Isoenzymes ,Renal Replacement Therapy ,Cross-Sectional Studies ,Italy ,Nephrology ,alpha-Galactosidase ,Cardiology ,Kidney Failure, Chronic ,Female ,Hypertrophy, Left Ventricular ,Hemodialysis ,business ,Kidney disease - Abstract
Background In Fabry disease, end-stage renal disease (ESRD) and severe neurologic and cardiac complications represent the leading causes of late morbidity and mortality. A comprehensive Italian nationwide survey study was conducted to explore changes in cardiac status and renal allograft function in Fabry patients on renal replacement therapy (RRT) and enzyme replacement therapy (ERT). Methods This study was designed as a cross-sectional survey study with prospective follow-up. Of the 34 patients identified via searches in registries, 31 males and 2 females who received RRT and ERT (agalsidase beta in 30 patients, agalsidase alpha in 3) were included. Left ventricular mass index (LVMI), interventricular septal thickness at end diastole (IVSD), left ventricular posterior wall thickness (LVPWT) and renal allograft function were assessed at ERT baseline and subsequently at yearly intervals. Results The patients in the dialysis and transplant groups had been started on dialysis at age 42.0 and 37.1 years (mean), respectively, and patients in the transplant group received their renal allograft at age 39.8 years (mean). The mean age at the start of ERT was similar, 44.1 and 44.6 years, respectively. The mean RRT follow-up was 61.1 and 110.6 months for dialysis and transplant patients, respectively, whereas the ERT duration was 45.1 and 48.4 months, respectively. Cardiac parameters increased in dialysis patients. In transplant patients, mean LVMI seemed to plateau during agalsidase therapy at a lower level as compared to baseline. Decline in renal allograft function was relatively mild (-1.92 ml/min/year). Agalsidase therapy was well tolerated. Serious ERT-unrelated events occurred more often in the dialysis group. Conclusions Kidney transplantation should be the standard of care for Fabry patients progressing towards ESRD. Transplanted Fabry patients on ERT may do better than patients remaining on maintenance dialysis. Larger, controlled studies in Fabry patients with ESRD will have to demonstrate if ERT is able to change the trajectory of cardiac disease and can preserve graft renal function.
- Published
- 2008
3. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
- Author
-
Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, and Cagnoli L
- Subjects
- Adult, Aged, Cross-Sectional Studies, Fabry Disease complications, Female, Humans, Hypertrophy, Left Ventricular etiology, Italy, Kidney Failure, Chronic etiology, Kidney Failure, Chronic therapy, Kidney Transplantation physiology, Male, Middle Aged, Prospective Studies, Recombinant Proteins therapeutic use, Registries, Ventricular Dysfunction, Left etiology, Fabry Disease drug therapy, Fabry Disease therapy, Isoenzymes therapeutic use, Renal Replacement Therapy, alpha-Galactosidase therapeutic use
- Abstract
Background: In Fabry disease, end-stage renal disease (ESRD) and severe neurologic and cardiac complications represent the leading causes of late morbidity and mortality. A comprehensive Italian nationwide survey study was conducted to explore changes in cardiac status and renal allograft function in Fabry patients on renal replacement therapy (RRT) and enzyme replacement therapy (ERT)., Methods: This study was designed as a cross-sectional survey study with prospective follow-up. Of the 34 patients identified via searches in registries, 31 males and 2 females who received RRT and ERT (agalsidase beta in 30 patients, agalsidase alpha in 3) were included. Left ventricular mass index (LVMI), interventricular septal thickness at end diastole (IVSD), left ventricular posterior wall thickness (LVPWT) and renal allograft function were assessed at ERT baseline and subsequently at yearly intervals., Results: The patients in the dialysis and transplant groups had been started on dialysis at age 42.0 and 37.1 years (mean), respectively, and patients in the transplant group received their renal allograft at age 39.8 years (mean). The mean age at the start of ERT was similar, 44.1 and 44.6 years, respectively. The mean RRT follow-up was 61.1 and 110.6 months for dialysis and transplant patients, respectively, whereas the ERT duration was 45.1 and 48.4 months, respectively. Cardiac parameters increased in dialysis patients. In transplant patients, mean LVMI seemed to plateau during agalsidase therapy at a lower level as compared to baseline. Decline in renal allograft function was relatively mild (-1.92 ml/min/year). Agalsidase therapy was well tolerated. Serious ERT-unrelated events occurred more often in the dialysis group., Conclusions: Kidney transplantation should be the standard of care for Fabry patients progressing towards ESRD. Transplanted Fabry patients on ERT may do better than patients remaining on maintenance dialysis. Larger, controlled studies in Fabry patients with ESRD will have to demonstrate if ERT is able to change the trajectory of cardiac disease and can preserve graft renal function.
- Published
- 2008
- Full Text
- View/download PDF
4. [From symptom to diagnosis: but not always!].
- Author
-
Giancaspro V, Cuzzola C, Lozupone VA, and Petrarulo F
- Subjects
- Humans, Male, Middle Aged, Kidney Calculi diagnosis
- Abstract
The classic presentation of acute renal colic is the onset of severe flank pain associated to homolateral groin irradiation. Very often these patients present typical clinical diagnosis patterns. We present a case of nephrolithiasis with atypical characteristics. The exact diagnosis has been possible only after the release of the stone.
- Published
- 2006
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.